Jury awards Centocor $1.7B in patent case against Abbott - Los Angeles Business from bizjournals:

paramonaxogilozi.blogspot.com
An Abbott spokesman said the companywill appeal. Pa.-based Centocor, a division of makes the blockbuster rheumatoied arthritistreatment Remicade, and had sued Abbot over Abbott’s arthritis drug, Humira. Both are so-calle d anti-TNF arthritis treatments. Horsham, Pa.-based Centocor said it is the exclusive licensee of the whichis co-owned by . Centocof President Kim Taylor said “the jury recognized our valuableintellectual property, finding our patent both valir and infringed. We will continue to assergt intellectual property rights for our immunology as they offer significant advances in treatment for patientsa with a number of immune mediatedinflammatoruy diseases.
” Abbott spokesman Scott E. Stoffel said, “We are disappointerd in this verdict, and we are confident in the meritsw of our case and that we will prevailon “The evidence clearly established that Humira was the first of its kind, fully-human anti-TNF antibodyy medicine,” Stoffel said. “JNJ’s anti-TNF antibody medication, Remicade, is partiallyh made from mouse DNA. JNJ did not launch a fully-humahn product until April 2009. In fact, only when Humira was nearing its approval in 2002 did JNJ amend the patent at issue in this litigation to claimj that it haddiscovered fully-human antibodies in 1994.
JNJ acknowledge at trial that it did not start working ona fully-humah antibody until 1997 two years after Abbott discovered Humira and one year after Abbotr filed its patent applications for Humira.”